NYSE: MEDMedifast Inc Stock
$12.05+0.35 (+2.99%)
Updated Jan 23, 2026
MED Price
$12.05
Fair Value Price
N/A
Market Cap
$132.44M
52 Week Low
$10.10
52 Week High
$16.66
P/E
602.5x
P/B
0.62x
P/S
0.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$429.70M
Earnings
$248.00k
Gross Margin
72.4%
Operating Margin
-0.65%
Profit Margin
0.1%
Debt to Equity
0.25
Operating Cash Flow
$7M
Beta
0.86
Next Earnings
Feb 24, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MED Overview
Medifast Incorporated manufactures weight loss, weight management, healthy living products, and other consumable health and nutritional products. Offerings include bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. Medifast was founded in 1980 and is headquartered in Baltimore, MD.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MED's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Personal Service
Industry Rating
D
MED
Ranked#9 of 10
Ranked#9 of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $93.43 | C | |
| $5.86 | C | |
| $57.99 | C |
Be the first to know about important MED news, forecast changes, insider trades & much more!
MED News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MED scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MED was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MED is poor value based on its earnings relative to its share price (602.5x), compared to the US market average (41.3x)
P/E vs Market Valuation
MED is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MED due diligence checks available for Premium users.
Valuation
MED price to earnings (PE)
For valuing profitable companies with steady earnings
Company
602.5x
Industry
39.71x
Market
41.3x
MED is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MED is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
MED price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.62x
Industry
8.08x
MED is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MED's financial health
Profit margin
Revenue
$89.4M
Net Income
-$2.3M
Profit Margin
-2.5%
MED's Earnings (EBIT) of -$2.79M... subscribe to Premium to read more.
Interest Coverage Financials
MED's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$268.2M
Liabilities
$53.5M
Debt to equity
0.25
MED's short-term assets ($207.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MED's short-term assets ($207.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MED's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MED's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.1M
Investing
-$14.3M
Financing
$0.0
MED's operating cash flow ($7.19M)... subscribe to Premium to read more.
Debt Coverage Financials
MED vs Personal Service Stocks
Medifast Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.